Entrada Therapeutics Stock (NASDAQ:TRDA)
Previous Close
$7.87
52W Range
$7.10 - $21.79
50D Avg
$10.70
200D Avg
$15.06
Market Cap
$295.49M
Avg Vol (3M)
$131.04K
Beta
0.03
Div Yield
-
TRDA Company Profile
Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. The company's lead product candidate is ENTR-601-44, which is in preclinical trail for the treatment of Duchenne muscular dystrophy and myotonic dystrophy type 1. It also engages in the development of EEV-PMO-CAG for the treatment of myotonic dystrophy type 1. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.
TRDA Performance
Peer Comparison
| Ticker | Company |
|---|---|
| IRON | Disc Medicine, Inc. |
| PHVS | Pharvaris N.V. |
| MOLN | Molecular Partners AG |
| RLYB | Rallybio Corporation |
| CRNX | Crinetics Pharmaceuticals, Inc. |
| PMVP | PMV Pharmaceuticals, Inc. |
| OPT | Opthea Limited |
| GLUE | Monte Rosa Therapeutics, Inc. |
| TYRA | Tyra Biosciences, Inc. |
| LRMR | Larimar Therapeutics, Inc. |
| GNTA | Genenta Science S.p.A. |
| EWTX | Edgewise Therapeutics, Inc. |
| CNTA | Centessa Pharmaceuticals plc |
| VIGL | Vigil Neuroscience, Inc. |
| CGEM | Cullinan Oncology, Inc. |
| PEPG | PepGen Inc. |
| THRD | Third Harmonic Bio, Inc. |